Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ADX10059 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| ADX10059 50 mg | EXPERIMENTAL | twice-daily |
| ADX10059 100 mg | EXPERIMENTAL | twice-daily |
| ADX10059 150 mg | EXPERIMENTAL | twice-daily |
| ADX10059 Matching Placebo | PLACEBO_COMPARATOR | twice-daily |
| ADX10059 120 mg | EXPERIMENTAL | Twice-daily |
| Name | Type | Description |
|---|---|---|
| ADX10059 | DRUG | oral administration |
| ADX10059 Matching Placebo | DRUG | oral administration |
Inclusion Criteria: * diagnosis of typical GERD * partial responder to a stable standard clinical symptoms control dose of PPI therapy * body mass index ≤ 32 kg/m2 Exclusion Criteria: * exclusively atypical symptoms of GERD * symptoms that have been shown not to be associated with GERD * erosive ...
ADX10059 is an investigational small molecule being studied for the treatment of gastroesophageal reflux disease (GERD). It has been evaluated in Phase 2 clinical trials as both an add-on therapy to proton pump inhibitors and as a monotherapy in patients with GERD.
ADX10059 is being developed by Addex Therapeutics Ltd, a biopharmaceutical company listed on the stock exchange under the ticker ADXN. The company has conducted Phase 2 clinical trials for this drug candidate in patients with gastroesophageal reflux disease.
ADX10059 is in Phase 2 clinical development. It has completed two Phase 2 trials for gastroesophageal reflux disease, with a total of 418 patients enrolled across studies in the United States and several European countries.
ADX10059 has completed two Phase 2 trials: NCT00810485, a study of ADX10059 as add-on therapy to proton pump inhibitors in 298 patients with GERD, and NCT00820079, a monotherapy study in 120 patients with GERD. Both trials were randomized, double-blind, and placebo-controlled.
ADX10059 is not FDA approved. It is an investigational drug that has completed Phase 2 clinical trials for gastroesophageal reflux disease. The drug remains in clinical development and has not been approved for any use.